Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 11:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–46 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: no anticoagulation Clear all
Not yet recruiting Phase 3 Interventional

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

NCT06628778
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Enoxaparin
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 23, 2026, 11:29 PM EDT
Completed No phase listed Observational

Study of Procoagulation Markers in Stroke Patients

NCT01811550
View directory record Official record
Conditions
Stroke, Hyperglycemia, Procoagulation Markers
Interventions
Glycemic Control
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
38
States / cities
Tucson, Arizona • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2020 · Synced Sep 23, 2026, 11:29 PM EDT
Not listed Not applicable Interventional

Hemofiltration in Burns: RESCUE (Randomized Controlled Evaluation of Hemofiltration in Adult Burn Patients With Septic Shock and Acute Renal Failure)

NCT01213914
View directory record Official record
Conditions
Burns, Hemofiltration, Kidney Failure, Acute, Shock, Septic
Interventions
An FDA approved continuous renal replacement device, Control Group
Device · Other
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 23, 2026, 11:29 PM EDT
Recruiting Phase 3 Interventional

DOAC - Dosing Options in AntiCoagulation Prophylaxis

NCT07005024
View directory record Official record
Conditions
Cancer, VTE (Venous Thromboembolism)
Interventions
Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 23, 2026, 11:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Pharmacodynamic Study of Rivaroxaban

NCT01743898
View directory record Official record
Conditions
Blood Clot
Interventions
Rivaroxaban, no anticoagulation
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2014 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

NCT02369653
View directory record Official record
Conditions
Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Apixaban, No systemic anticoagulant prophylaxis
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
1 Year to 17 Years
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
64
States / cities
Phoenix, Arizona • Duarte, California • Loma Linda, California + 56 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 23, 2026, 11:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World

NCT04276441
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
Device
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
65 Years and older
Enrollment
34,244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Not applicable Interventional

EHR-Embedded Decision Support to Prevent Stroke in Patients With AF

NCT04099485
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Electronic Health Record Best Practice Advisory
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Sep 23, 2026, 11:29 PM EDT
Not yet recruiting No phase listed Observational

Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

NCT06783868
View directory record Official record
Conditions
Atrial Fibrillation, Stroke
Interventions
Catheter Ablation, Market-approved AVNB, OAC and AAD
Device · Drug
Lead sponsor
Kansas City Heart Rhythm Research Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Sep 23, 2026, 11:29 PM EDT
Completed No phase listed Observational

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

NCT03292666
View directory record Official record
Conditions
Venous Thromboembolism, Anticoagulants and Bleeding Disorders
Interventions
Oral Anticoagulant
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
39,603 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Oakland, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 23, 2026, 11:29 PM EDT
Recruiting Phase 4 Interventional

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

NCT05180773
View directory record Official record
Conditions
Peripartum Cardiomyopathy, Postpartum
Interventions
Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo
Drug
Lead sponsor
Dennis M. McNamara, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
64
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Phase 4 Interventional Results available

Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

NCT03140631
View directory record Official record
Conditions
Atrial Fibrillation, Catheter Ablation
Interventions
Protamine Sulfate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Not applicable Interventional Results available

Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence

NCT02690649
View directory record Official record
Conditions
Atrial Fibrillation, Medication Adherence
Interventions
Health Messaging (Non-Procedural)
Other
Lead sponsor
Tammy Toscos
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 23, 2026, 11:29 PM EDT
Recruiting Phase 4 Interventional

Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress

NCT03968393
View directory record Official record
Conditions
Stroke, Atrial Fibrillation
Interventions
Non-vitamin K oral anticoagulant (NOAC)
Drug
Lead sponsor
Population Health Research Institute
Other
Eligibility
55 Years and older
Enrollment
2,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Not applicable Interventional Results available

Comparison of Two Pulmonary Embolism Treatments

NCT05684796
View directory record Official record
Conditions
Pulmonary Embolism Acute
Interventions
Anticoagulation, mechanical aspiration thrombectomy
Drug · Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Tucson, Arizona • Los Angeles, California • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 23, 2026, 11:29 PM EDT
Not yet recruiting Phase 4 Interventional

Prospective Study: TXA, Anticoagulant, Orthopaedic Trauma

NCT07116395
View directory record Official record
Conditions
Patients Undergoing Operative Fixation of Long Bone Fractures Within the Community Medical Centers System
Interventions
Tranexamic Acid (TXA)
Drug
Lead sponsor
Arbi Nazarian, MD
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Phase 4 Interventional Results available

Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation

NCT02608099
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Interrupted apixaban, Uninterrupted apixaban
Drug
Lead sponsor
Baim Institute for Clinical Research
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
19
States / cities
Huntsville, Alabama • Mission Viejo, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Phase 2Phase 3 Interventional

Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)

NCT04372589
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
Heparin
Drug
Lead sponsor
University of Manitoba
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Atlanta, Georgia • Chicago, Illinois • Jefferson, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 23, 2026, 11:29 PM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 23, 2026, 11:29 PM EDT
Recruiting Early Phase 1 Interventional

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

NCT06615596
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation
Behavioral · Drug · Procedure
Lead sponsor
China National Center for Cardiovascular Diseases
Government
Eligibility
18 Years and older
Enrollment
3,160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis Patients

NCT04042324
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Triferic, Heparin
Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 23, 2026, 11:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anticoagulation Medical Home

NCT02870296
View directory record Official record
Conditions
Venous Thromboembolism, Patient-Centered Care
Interventions
Enhanced Assessment and Education
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 23, 2026, 11:29 PM EDT